Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder
Women aged between 21 and 65 years;
Premenopausal or postmenopausal women may be included;
May or may not be using female sex hormones (estrogen with or without progesterone, or their derivatives);
Women who have previously had sexual experiences with orgasm, desire, and arousal, for a minimum period of two years;
Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study;
Women who do not agree to attempt sexual activity at least twice a week while taking the study medication;
Serious relationship problems, defined as a CSI-16 score below 51.5, of non-sexual origin, and which, in the investigator's opinion, may influence sexual activities;
History of unresolved sexual trauma or abuse, that could interfere with participation or the results of the study;